Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14460414 | 1.00 | L3MBTL1 (0.32) | L3MBTL1KDM4EATMPTGER4MEN1 | |
| SCHEMBL14460209 | 0.90 | KDM4E (0.37) | L3MBTL1KDM4EATM | |
| SCHEMBL14460199 | 0.90 | KDM4E (0.37) | L3MBTL1KDM4EATM | |
| SCHEMBL14460273 | 0.89 | KDM4E (0.33) | L3MBTL1KDM4EATM | |
| SCHEMBL14460410 | 0.89 | KDM4E (0.33) | L3MBTL1KDM4EATM | |
| SCHEMBL14460419 | 0.89 | KDM4E (0.36) | L3MBTL1KDM4EATM | |
| SCHEMBL2601517 | 0.89 | L3MBTL1 (0.32) | L3MBTL1KDM4EATMMEN1MAPT | |
| SCHEMBL14460279 | 0.89 | KDM4E (0.32) | L3MBTL1KDM4EATM | |
| SCHEMBL10034190 | 0.89 | L3MBTL1 (0.32) | L3MBTL1KDM4EATMMEN1MAPT | |
| SCHEMBL14460418 | 0.89 | KDM4E (0.32) | L3MBTL1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431251-B2 | Heterocyclic compound and organic light-emitting device comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2013-04-30 | — | — | US | disclosed |
| US-20130001524-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20130001524-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130001524-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING THE SAME | C9, C1S, C5 | L3MBTL1 99/4885KDM4E 3752/4885ATM 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.